Department of Rheumatology, Geffen School of Medicine, University of California, Los Angeles, California, USA.
Muscle Nerve. 2012 Oct;46(4):496-505. doi: 10.1002/mus.23384.
In this study we determined the health-care costs and resource utilization associated with idiopathic inflammatory myopathies (IIMs) in a large managed care plan in the USA.
Myositis subjects ≥18 years of age with claims-based evidence of IIMs were identified from a health plan database. Subjects were matched with unaffected controls, and costs and resource use were determined during a 12-month period.
A total of 1781 newly diagnosed IIM subjects were matched to 5343 controls, and 2697 subjects with existing disease were matched to 8091 controls. Mean overall annual medical costs were higher among newly diagnosed subjects ($16,319 vs. $4926, P < 0.001) and subjects with an existing IIM ($15,539 vs. $5210, P < 0.001) in comparison to controls. IIM subjects had significantly higher mean counts of ambulatory visits, specialist visits, and inpatient hospital stays compared with controls (all P < 0.001).
Our analysis suggests that IIMs have increased medical costs and resource use.
本研究旨在确定美国大型管理式医疗计划中特发性炎性肌病(IIM)相关的医疗保健成本和资源利用情况。
从医疗保险数据库中确定了符合以下条件的≥18 岁的肌炎患者,有基于索赔的 IIM 证据。将患者与未受影响的对照组相匹配,并在 12 个月内确定成本和资源利用情况。
共匹配了 1781 例新诊断的 IIM 患者和 5343 例对照组,2697 例患有现有疾病的患者和 8091 例对照组。与对照组相比,新诊断的患者($16319 比 $4926,P<0.001)和患有现有 IIM 的患者($15539 比 $5210,P<0.001)的总体年度医疗费用更高。与对照组相比,IIM 患者的门诊就诊、专科就诊和住院治疗的平均次数明显更高(均 P<0.001)。
我们的分析表明,IIM 会增加医疗成本和资源使用。